Title:Multi-Endogenous Nanoformulation for Endocannabinoid and Hormonal Modulation of Key Signaling Pathways in Resistant Hypertension
Volume: 32
Issue: 20
Author(s): Virna Margarita Martín Gimenez, Sebastian García Menendez and Walter Manucha*
Affiliation:
- Área de Farmacología, Departamento de Patología, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza 5500, Argentina
- Centro Científico Tecnológico, Pathology and Pharmacology Department, Mendoza 5500, Argentina
Keywords:
Hypertension, nanoformulation, multiendogenous treatment, nanopharmacology, vitamin D, melatonin, anandamide.
Abstract: Despite notable advances in the development of synthetic antihypertensive therapies, resistant hypertension
remains a complex and challenging condition. Its persistence is attributed to multifactorial resistance
mechanisms involving several key signaling pathways, including Hsp70, WT1, AT1, and iNOS. A promising
therapeutic strategy involves the simultaneous modulation of these pathways using endogenous bioactive compounds
delivered via controlled and sustained-release nanosystems. Such nanoformulations enable the co-delivery
of multiple agents, enhancing their bioavailability, stability, and therapeutic precision. This multifaceted
approach allows for more effective modulation of the underlying pathophysiological processes of hypertension,
including inflammation, oxidative stress, and vascular dysfunction. By integrating these compounds into
a single delivery platform, nanoformulations may offer a significant advancement in the treatment of resistant
hypertension and related cardiovascular disorders. Future research should prioritize the optimization of these
delivery systems and the assessment of their efficacy in clinically relevant models.
